Recent updates in pulmonary hypertension: New treatment options, inhaled therapy and more - Healio

Recent updates in pulmonary hypertension: New treatment options, inhaled therapy and more - Healio

Recent updates in pulmonary hypertension: New treatment options, inhaled therapy and more - Healio

Posted: 19 Aug 2020 12:00 AM PDT

August 19, 2020

2 min read

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The Healio editors have compiled a list of recent updates in the management and treatment of pulmonary hypertension.

Recent news includes an update from the TRITON study on initial triple oral therapy compared with double therapy in newly diagnosed PAH; new data on inhaled treprostinil and inhaled nitric oxide; selexipag in children; and more. Read these articles, and others, below.

Breaking News
Source: Adobe Stock.

Initial triple therapy vs. double may improve outcomes in newly diagnosed PAH: TRITON

In patients with newly diagnosed PAH, initial triple oral therapy, compared with double therapy, both improved hemodynamics, NT-proBNP and functional capacity, with no difference between strategies at 26 weeks. Read more

Inhaled nitric oxide at higher dose shows benefit in pulmonary hypertension, fibrotic ILD

Pulsed, inhaled nitric oxide at a higher dose was safe and well tolerated, and resulted in improvements in physical activity and other outcomes in patients at risk for pulmonary hypertension-associated fibrotic interstitial lung disease. Read more

Inhaled treprostinil improves QOL, other exploratory outcomes in patients with PAH

New exploratory endpoint data from the INSPIRE study show improvements after 2 months of treatment with inhaled treprostinil in quality of life, 6-minute walk distance and New York Heart Association functional class. Read more

New research widens continuum of risk associated with PVR in pulmonary hypertension

New data expand the range of pulmonary vascular resistance associated with mortality and heart failure in patients at risk for pulmonary hypertension undergoing right heart catheterization. Read more

Selexipag well tolerated, safe in children with PAH

Use of oral add-on selexipag in children was well tolerated, safe and improved PAH outcomes, according to data published in The Journal of Heart and Lung Transplantation. Read more

PAH outcomes improved in specialty care centers

Patients with PAH treated in a specialty care center had improved mortality and hospitalization, according to a study published in CHEST. Read more

Inhaled treprostinil improves outcomes in ILD-associated pulmonary hypertension

Inhaled treprostinil was well tolerated and significantly improved exercise capacity and other clinical outcomes over 16 weeks in patients with pulmonary hypertension associated with ILD, according to results of the INCREASE study. Read more

Sotatercept decreases pulmonary vascular resistance in PAH: PULSAR

In the phase 2 PULSAR trial, treatment with sotatercept for 24 weeks resulted in greater reduction in pulmonary vascular resistance than placebo in patients with PAH on stable background therapies. Read more

Exercise rehabilitation low among US veterans with pulmonary hypertension

Few patients with primary PAH were treated with exercise rehabilitation in the form of pulmonary or cardiac rehabilitation. Read more

Read more about:

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Comments

Post a Comment

Popular posts from this blog

Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor

Image
Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Posted: 11 Jul 2019 12:00 AM PDT For patients with severe hypoxemia with pulmonary hypertension or right heart dysfunction, inhaled epoprostenol through high-flow nasal cannula increases oxygenation, according to a study published in Pharmaceutics . The researchers of this retrospective study assessed the effect of inhaled epoprostenol using a high-flow nasal cannula on oxygenation and future mechanical ventilation in patients with hypoxemia comorbid with pulmonary hypertension or right heart dysfunction in an intensive care unit setting. A chart review was completed on adult patients who were admitted into the respiratory care department of the Rush University Medical Center for severe hypoxemia between July 2015 and April 2018 and treated with inha...
Read more

Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News

Image
Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Growing Doubt, Uncertainty Over PDE5i Use in Left Heart Disease - Medscape AnMed Health gains national recognition through the Pulmonary Hypertension Association - WSPA.com Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Posted: 12 Jun 2019 05:00 AM PDT The U.S. Food and Drug Administration (FDA) has approved Novitium Pharma 's generic sildenafil for oral suspension at a dose of 10 mg/mL for the treatment of pulmonary arterial hypertension (PAH). This product, which had been designated a competitive generic therapy by the FDA, is the first approved generic equivalent to Pfizer 's Revatio , a vasodilator agent that induces blood ves...
Read more

Analysis: Large pharma companies do little new drug innovation - STAT

Image
Analysis: Large pharma companies do little new drug innovation - STAT Analysis: Large pharma companies do little new drug innovation - STAT Gene Therapy Takes Center Stage at 2019 NORD Summit - Pulmonary Hypertension News People Living With Type 2 Diabetes Want Information and Empathy From Their Doctors More Than New Medications - PRNewswire Analysis: Large pharma companies do little new drug innovation - STAT Posted: 10 Dec 2019 01:51 AM PST L arge pharmaceutical companies oppose legislation being considered by Congress to lower the prices of prescription drugs. Reducing their revenues, they contend, will reduce their investment in drug development and the discovery of new medicines, and thus lead to a decline in drug innovation. If that argument is credible, there should be evidence to show that the large pharmaceutical companies are responsible for discovering innovative new drugs. To test that claim, we examined the...
Read more